Healthcare / Diagnostics & ResearchKOSDAQ
$2805.00
-100.00 (-3.44%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-11.3B · quality 70.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
11/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$50.3B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-79.8%
↓Gross Margin
100.0%
↑Debt/Equity
0.79
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+1.5%
FCF CAGR
—
FCF margin
-350.4%
FCF / Net income
1.04x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4.28B · net income $-14.50B · FCF $-15.01B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4.28B | $4.28B | $3.93B | $4.10B | $4.09B |
| Net Income | $-14.50B | $-14.50B | $-14.14B | $-14.08B | $-10.21B |
| EBITDA | $-11.60B | $-11.60B | $-12.23B | $-13.19B | $-9.38B |
| EPS | -897.00 | -897.00 | -1040.91 | -1169.73 | -982.61 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | -313.4% | -313.4% | -350.7% | -284.3% | -248.4% |
| Net Margin | -338.4% | -338.4% | -359.8% | -343.4% | -249.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.79 | 0.79 | 3.45 | 0.16 | 0.59 |
| Current Ratio | 1.77 | 1.77 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-15.01B | $-15.01B | $-11.31B | $-10.46B | $-9.01B |
| Returns | |||||
| ROE | -79.8% | -79.8% | -385.9% | -120.3% | -469.6% |
| Valuation | |||||
| P/B | 2.49 | 2.49 | 22.98 | 30.02 | — |
| Growth & Yield | |||||
| Revenue Growth | 9.0% | 9.0% | -4.2% | 0.2% | — |
| EPS Growth | 13.8% | 13.8% | 11.0% | -19.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-53.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-1040.91 → -897.00
Residual
-53.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.